Substance / Medication

Bosentan

Overview

Active Ingredient
bosentan
RxNorm CUI
75207

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

55 trials linked to this intervention

55
Total Trials
13
Recruiting
16
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Bosentan in the treatment of persistent pulmonary hypertension in newborns: a systematic review and meta-analysis.
Gao Ning, Lv Yuanyuan, Cui Yanbin et al. · Cardiol Young · 2024
PMID: 38329072Meta-Analysis
Bosentan and ambrisentan in the treatment of idiopathic pulmonary fibrosis: a meta-analysis.
Li H-F, Wang J-X, Xie Z-F et al. · Eur Rev Med Pharmacol Sci · 2024
PMID: 38375723Meta-Analysis
Efficacy and safety of bosentan in the treatment of persistent pulmonary hypertension of the newborn: a Metaanalysis.
Li Ling-Xue, Wei Bing, Yang Ming et al. · Zhongguo Dang Dai Er Ke Za Zhi · 2022
PMID: 35351265Meta-AnalysisFull text (PMC)
Systematic review and cost-effectiveness of bosentan and sildenafil as therapeutic drugs for pediatric pulmonary arterial hypertension.
Chen Tingting, Chen Jiahe, Chen Chaoxin et al. · Pediatr Pulmonol · 2021
PMID: 33856119Meta-Analysis
Efficacy and Safety of Long-Term Oral Bosentan in Different Types of Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis.
Kuang Hong-Yu, Li Qiang, Du Hua-An et al. · Am J Cardiovasc Drugs · 2021
PMID: 32918210Meta-Analysis
Cost Effectiveness of Bosentan for Pulmonary Arterial Hypertension: A Systematic Review.
You Ruxu, Qian Xinyu, Tang Weijing et al. · Can Respir J · 2018
PMID: 30581511Meta-AnalysisFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Bosentan (substance)
SNOMED CT
385559004
UMLS CUI
C0252643
RxNorm CUI
75207

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
55
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.